CIAM
GLUE icon

Caitong International Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Caitong International Asset Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$968 Buy
+40
New +$756 ﹤0.01% 1556
2026
Q1 		– Sell
-27
Closed -$423 – 2767
2025
Q4 		$423 Buy
+27
New +$364 ﹤0.01% 1501
2025
Q3 		– Sell
-1,066
Closed -$4.81K – 2161
2025
Q2 		$4.81K Buy
+1,066
New +$4.75K ﹤0.01% 1033
2025
Q1 		– Sell
-37
Closed -$257 – 2303
2024
Q4 		$257 Buy
+37
New +$278 ﹤0.01% 1560

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caitong International Asset Management's GLUE Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Monte Rosa Therapeutics (GLUE) in Q2 2026: 40 shares worth $968. The stake represents ﹤0.01% of the portfolio and ranks #1556 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in GLUE as recently as Q4 2025.

Caitong International Asset Management first reported a position in GLUE in Q4 2024 and has held it in 4 quarters since. The position peaked at $4.81K in Q2 2025. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Caitong International Asset Management held 40 shares of Monte Rosa Therapeutics worth $968 as of Q2 2026.
  • Monte Rosa Therapeutics was a new Caitong International Asset Management position in Q2 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1556 holding.
  • Caitong International Asset Management first reported a position in Monte Rosa Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Caitong International Asset Management's Monte Rosa Therapeutics position peaked at $4.81K in Q2 2025.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.